Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2001-12-04
2004-11-23
Nickol, Gary (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S350000
Reexamination Certificate
active
06821947
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the fields of tumor biology and molecular biology, and to a method of treating angiogenesis-related diseases or conditions and, more particularly, to the inhibition of neovascularization and tumor growth and metastasis in vivo.
BACKGROUND OF THE INVENTION
Perlecan is a modular proteoglycan that participates in the formation and maintenance of basement membranes in various organs (1,2). It is a major heparan sulfate proteoglycan (HSPG) secreted by endothelial cells and is a potent inhibitor of smooth muscle cell proliferation, a biological function mediated by perlecan's block of fibroblast growth factor 2 (FGF2) activity (13) and Oct-1 gene expression (14). Perlecan has been shown to play a critical role in regulating the vascular response to injury in vivo (17).
Angiogenesis is one of the most important events in tumor progression and is greatly influenced by cell-matrix interactions taking place at the surface of the endothelial cells and at the tumor-matrix boundaries (31). HSPGs act as depots for pro- and anti-angiogenic factors and, in concert with members of the FGF and vascular endothelial growth factor (VEGF) families and their receptors, modulate various aspects of angiogenesis (9). Interestingly, various angiogenesis inhibitors have been found to be proteolytically-processed forms of basement membrane collagens types IV, XV and XVIII, the latter two being chondroitin and HSPGs, respectively (32).
The invention presented herein describes a potent inhibitor of angiogenesis: the carboxyl terminus domain, domain V, of perlecan. This fragment, “endorepellin,” inhibits angiogenesis and is active at nanomolar concentrations. Endorepellin interferes with endothelial cells' adhesive properties for various substrata, including, but not limited to, fibronectin and fibrillar collagen. Endorepellin, thus, represents a novel anti-angiogenic tool for the treatment of diseases or conditions associated with movement, migration and adhesion of cells, including diseases that involve angiogenesis such as, but not limited to, tumor metastasis and growth. The present invention provides endorepellin, analogs and fragments thereof, for use in inhibiting angiogenesis.
Abbreviations
“HSPG” means “heparan sulfate proteoglycans”
“HUVEC” means “human umbilical vein endothelial cells”
“CAM” means “chicken chorioallantoic membrane
“FGF” means “fibroblast growth factor”
“VEGF” means “vascular endothelial cell growth factor”
“LG” means “laminin-type G”
“EG” means “epidermal growth factor-like”
Definitions
“patient” as used herein can be one of many different species, including but not limited to, mammalian, bovine, ovine, porcine, equine, rodent and human.
“analog” as used herein is a derivative or modification of the native sequence. One skilled in the art may prepare such analogs wherein the native sequence is modified by resultant single or multiple amino acid substitutions, additions or deletions. All such modifications resulting in a derivative of endorepellin are included within the scope of the invention, provided that the molecule retains angiogenesis-inhibiting activity.
“substantial sequence homology” means at least approximately 60% homology between the amino acid residue sequence in the endorepellin analog or derivative sequence and that of endorepellin sequence.
“anti-angiogenesis activity” and “angiogenesis-inhibiting activity” refers to the ability of a molecule to inhibit the growth of blood vessels.
“angiogenesis-mediated disease” refers to the unregulated growth of new blood vessels that causes a disease or exacerbates an existing condition.
REFERENCES:
patent: 5958883 (1999-09-01), Snow
patent: 6284726 (2001-09-01), Colman et al.
patent: WO 99/06054 (1999-02-01), None
Murdoch et al (J. Biol. Chem. 1992;267(12):8544-8557).*
Auerbach et al (Clinical Chemistry 2003 49(1):32-40).*
Reiger et al (Glossary of Genetics and Cytogenetics, Classical and Molecular, 4th Ed., Springer-Verlay, Berlin, 1976.*
Dermer (Bio/Technology 1994; 12:320).*
Freshney (Culture of Animal Cells, A Manual of Basic Techniques, Alan R. Liss, Inc., 1983, New York, p4).*
D. M. Noonan, et al.J.Biol.Chem.266, 22939-22947 (1991).
P. Kallunki, et al.J.Cell Biol.116, 559-571 (1992).
A. D. Murdoch, et al.,J.Biol.Chem.267, 8544-8557 (1992).
D. Aviezer, et al.,Cell79, 1005-1013 (1994).
J.M. Whitelock, et al.,J. Biol. Chem.271, 10079-10086 (1996).
M.A. Nugent, et al.,Proc. Natl. Acad. Sci. USA97, 6722-6727 (2000).
R. V. Iozzo,J.Cell Biol.99, 403-417 (1984).
I. R. Cohen, et al.,Cancer Res.54, 5771-5774 (1994).
D. Aviezer, et al.,Mol. Cell. Biol.17, 1938-1946 (1997).
R. Adatia, et al.,Ann. Oncol.8, 1257-1261 (1997).
Sharma, B. et al.,J.Clin. Invest.102, 1599-1608 (1998).
M. Mongiat, et al.,J.Biol.Chem.275, 7095-7100 (2000).
S. Gauer, et al.,Eur.J.Cell Biol.70, 233-242 (1996).
J. M. Whitelock, et al.,Matrix Biol.18, 163-178 (1999).
M. S. O'Reilly,Cell 88, 277-285 (1997).
W. Halfter, et al.,J.Biol.Chem.273, 25404-25412 (1998).
J. Saarela, et al.,Am.J.Pathol.153, 611-626 (1998).
N. Yamaguchi, et al.,EMBO J.18, 4414-4423 (1999).
W. Risau,Nature 386, 671-674 (1997).
J. C. Brown, et al.,Eur.J.Biochem.250, 39-46 (1997).
T. Sasaki, et al.,EMBO J.17, 4249-4256 (1998).
T. Sasaki, et al.,J.Mol.Biol.301, 1179-1190 (2000).
Z. Chang, et al.,Am.J.Pathol.155, 71-76 (1999).
K. Lundmark, et al.,J.Cell.Physiol.188, 67-74 (2001).
M. Mathiak, et al.,Cancer Res.57, 2130-2136 (1997).
A. G. Marneros, et al.,Matrix Biol.20, 337-345 (2001).
J. Xu, et al.,J.Cell Biol.154, 1069-1079 (2001).
R. V. Iozzo,J.Clin.Invest.108, 165-167 (2001).
O. Oda, et al.,Clin.Chim.Acta255, 119-132 (1996).
M. Mongiat, et al.,J.Biol.Chem.276, 10263-10271 (2001).
Drinker Biddle & Reath LLP
Nickol Gary
Thomas Jefferson University
Yaen Christopher
LandOfFree
Endorepellin: methods and compositions for inhibiting... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Endorepellin: methods and compositions for inhibiting..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Endorepellin: methods and compositions for inhibiting... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3337887